Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
144,23 ^USD	-0,28 %		-4,66 %	+17,51 %

06/10	Cognizant et Gilead signent une extension de cinq ans de leur partenariat technologique couvrant le DevOps et les outils d’IA	MT
05/10	Nurix Therapeutics et Gilead Sciences conviennent d’une prolongation de deux ans de la période de recherche pour un programme en oncologie	MT

Autres langues

06/10	Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools
05/10	Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program
02/10	Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
28/09	Mirum's liver infection drug lowers virus levels in late-stage study
25/09	HEALTH ROUNDS-Genetic discovery yields clues toward reversal of Alzheimer's brain damage
24/09	Hackensack Meridian Center for Discovery and Innovation, Gilead Sciences and the Rockefeller University Collaborate to Research Oral Treatments for Mosquito-Borne Flaviviruses
18/09	Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
18/09	Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2%
16/09	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing
16/09	Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited
16/09	Gilead Sciences Expands Licensing Agreements for HIV Treatment
16/09	Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
15/09	Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
15/09	Gilead Sciences Expands Lenacapavir Access to 14 Countries
15/09	Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
15/09	Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
08/09	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead
08/09	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
08/09	Assembly Biosciences, Inc. and Gilead Sciences, Inc. Exercise U.S. Profit-Share Option for HSV Helicase-Primase Inhibitor Program
08/09	Gilead Sciences Opens Research Center At Foster City Headquarters
08/09	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
07/09	Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv
03/09	AbbVie's blood cancer therapy lowers disease progression, death risk in trial
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
28/08	Afternoon Meeting: Warsh entra en escena